Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax in the Department of Oncology. Robert was successful in his application for a CRUK pre-doctoral research bursary.

Pre-doctoral research bursaries are awarded biannually by Cancer Research UK to "provide short-term funding to allow clinicians and other health professionals to get involved in research projects early in their career". This scheme was ideal for Robert Watson, a junior doctor with an interest in academic research. He is currently taking a year out from his clinical training to conduct research in the laboratory of Benjamin Fairfax at the MRC WIMM, and is interested in applying for a PhD at a later date. "This CRUK grant will support my research this year" explains Rob "It will give me a chance to experience research and develop my skills, and hopefully gather preliminary data that will help me apply for a PhD".

The laboratory of Dr Benjamin Fairfax is examining the genetic changes that accompany the treatment of cancer with immunotherapies. During his time in the lab, Robert will be using sequencing techniques to investigate changes to the T cell repertoire during checkpoint inhibitor treatments. "I am very keen to work in the area of immunoncology and to further develop my skills in genetic medicine and computational biology, so this projects fits well with the lab's strategy and my own personal aims", says Robert. The successful bid will provide £25,000 towards the project's research expenses.

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.